id="c_9">9
Marazziti D, Akiskal HS, Rossi A, Cassano GB. Alteration of the platelet serotonin transporter in romantic love. Psychol Med. 1999 May; 29(3): 741–5.
10
Bentall RP. A proposal to classify happiness as a psychiatric disorder. Journal of Medical Ethics. 1992; 18(2): 94–98.
11
https://www.youtube.com/watch?v=G_Qwp2GdB1M
12
Dima D, Roiser JP, Dietrich DE, Bonnemann C, Lanfermann H, Emrich HM, Dillo W. Understanding why patients with schizophrenia do not perceive the hollow-mask illusion using dynamic causal modelling. Neuroimage. 2009 Jul 15; 46(4): 1180–6. doi: 10.1016/j.neuroimage.2009.03.033.Epub 2009 Mar 24.
13
Rosenhan DL. On being sane in insane places. Science. 1973 Jan 19; 179(4070): 250–8.
14
Progler Y. Mental illness and social stigma: notes on "How Mad Are You?" Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences. 2009; 14(5): 331–334.
15
Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies. J Affect Disord. 2009. Se; 117(1–2): 1–17.
16
Contribution of depression to cognitive impairment and dementia in older adults. Neurologist. 2007 May; 13(3): 105–17.
17
American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (Fifth ed.). Arlington, VA: American Psychiatric Publishing, p. 20. ISBN978–0–89042–555–8.
18
Dalgleish T. The emotional brain. Nat Rev Neurosci. 2004 Jul; 5(7): 583–9. Review.
19
Mega MS, Cummings JL, Salloway S, Malloy P. The limbic system: an anatomic, phylogenetic, and clinical perspective. J Neuropsychiatry Clin Neurosci. 1997 Summer; 9(3): 315–30. Review.
20
Robert Sapolsky (2005). "Biology and Human Behavior: The Neurological Origins of Individuality, 2nd edition". The Teaching Company, p. 13 & 14 of Guide Book.
21
Nichols DE. Hallucinogens. Pharmacol Ther. 2004 Feb; 101(2): 131–81. Review.
22
Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol. 2003 Jun; 63(6): 1223–9.
23
Kennett GA, Ainsworth K, Trail B, Blackburn TP. BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology. 1997 Feb; 36(2): 233–9.
24
Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5; 102(23): 2836–41.
25
de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Camí J. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004 Apr; 26(2): 137–44. Review.
26
Hofmann A. (1983). LSD, my problem child: Reflections on sacred drugs, mysticism, and science. Los Angeles: J. P. Tarcher. P. 21.
27
Andersson A, Wiréhn A-B, Ölvander C, Ekman DS, Bendtsen P. Alcohol use among university students in Sweden measured by an electronic screening instrument. BMC Public Health. 2009;9:229. doi: 10.1186/1471-2458-9-229.
28
Kellett J, Kokkinidis L. Extinction deficit and fear reinstatement after electrical stimulation of the amygdala: implications for kindling-associated fear and anxiety. Neuroscience. 2004; 127(2): 277–87.
29
Ghaemi SN. The rise and fall of the biopsychosocial model. Br J Psychiatry. 2009 Jul; 195(1): 3–4. doi: 10.1192/bjp.bp.109.063859.
30
Haygarth, John. (1800). Of the imagination, as a cause and as a cure of disorders of the body; exemplified by fictitious tractors, and epidemical convulsions. Read to the Literary and Philosophical Society of Bath. By John Haygarth, M.D. … Bath: printed by R. Cruttwell; and sold by Cadell and Davies, London.
31
Beecher HK. The powerful placebo. J Am Med Assoc. 1955; 159(17): 1602–6.
32
Howick J, Friedemann C, Tsakok M, et al. Are treatments more effective than placebos? A systematic review and meta-analysis. PLoS ONE. 2013; 8(5): e62599.
33
Linde K, Fässler M, Meissner K. Placebo interventions, placebo effects and clinical practice. Philos Trans R Soc Lond, B, Biol Sci. 2011; 366(1572): 1905–12.
34
Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry. 2008; 65(2): 220–31.
35
Oken BS. Placebo effects: clinical aspects and neurobiology. Brain. 2008; 131(Pt 11): 2812–23.
36
Matre
